MX2016009475A - Composiciones efectivas contra la conjuntivitis viral. - Google Patents

Composiciones efectivas contra la conjuntivitis viral.

Info

Publication number
MX2016009475A
MX2016009475A MX2016009475A MX2016009475A MX2016009475A MX 2016009475 A MX2016009475 A MX 2016009475A MX 2016009475 A MX2016009475 A MX 2016009475A MX 2016009475 A MX2016009475 A MX 2016009475A MX 2016009475 A MX2016009475 A MX 2016009475A
Authority
MX
Mexico
Prior art keywords
effective against
composition effective
against viral
viral conjunctivitis
subtype
Prior art date
Application number
MX2016009475A
Other languages
English (en)
Inventor
Angelika Bodenteich
Prieschl-Grassauer Eva
Morokutti-Kurz Martina
Grassauer Andreas
Nakowitsch Sabine
König-Schuster Marielle
KOLLER Christiane
Pilotaz Frederic
Original Assignee
Nicox Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Sa filed Critical Nicox Sa
Publication of MX2016009475A publication Critical patent/MX2016009475A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica para usarse como un medicamento en el tratamiento tópico profiláctico o terapéutico de infecciones oculares causadas por el adenovirus del subtipo D o el virus de la influenza A del subtipo H7; la composición en su formulación lista para usarse comprende iota-carragenano como un ingrediente antiviral activo y está sustancialmente libre de una sal de haluro metálico o contiene no más de 0.5% p/v de una sal de haluro metálico.
MX2016009475A 2014-01-22 2015-01-20 Composiciones efectivas contra la conjuntivitis viral. MX2016009475A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14152188.0A EP2898888B8 (en) 2014-01-22 2014-01-22 Composition comprising iota-carrageenan against viral Conjunctivitis
PCT/EP2015/051015 WO2015110429A1 (en) 2014-01-22 2015-01-20 Composition effective against viral conjunctivitis

Publications (1)

Publication Number Publication Date
MX2016009475A true MX2016009475A (es) 2017-01-16

Family

ID=49956098

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009475A MX2016009475A (es) 2014-01-22 2015-01-20 Composiciones efectivas contra la conjuntivitis viral.

Country Status (15)

Country Link
US (1) US10220055B2 (es)
EP (2) EP2898888B8 (es)
JP (1) JP6635343B2 (es)
CN (1) CN105939720B (es)
CA (1) CA2937402C (es)
DK (1) DK2898888T3 (es)
ES (2) ES2734269T3 (es)
HR (1) HRP20191050T1 (es)
HU (1) HUE044329T2 (es)
MX (1) MX2016009475A (es)
PL (1) PL2898888T3 (es)
PT (1) PT2898888T (es)
RS (1) RS58731B1 (es)
SI (1) SI2898888T1 (es)
WO (2) WO2015110429A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6794454B2 (ja) * 2015-09-25 2020-12-02 オコジェン、インコーポレイテッドＯｋｏｇｅｎ， Ｉｎｃ． ランピルナーゼおよび／またはアンフィナーゼを使用するウイルス性結膜炎の処置

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783446A (en) * 1985-11-22 1988-11-08 Neushul Mariculture Incorporated Method for the treatment of AIDS virus and other retroviruses
FR2653021A1 (fr) * 1989-10-17 1991-04-19 Merck Sharp & Dohme Composition ophtalmique aqueuse liquide a transition de phase liquide-gel.
EP0495421B1 (en) * 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
IT1313610B1 (it) * 1999-08-09 2002-09-09 S I F I Societa Ind Farmaceuti Processo per la preparazione di formulazioni acquose per uso oftalmico
AR031135A1 (es) * 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
DE10352137A1 (de) 2003-11-04 2005-06-16 Beschorner, Katharina, Dr. Verwendung sulfatierter Hyaluronsäure
DE102005046769A1 (de) 2005-09-29 2007-04-05 Berlin-Chemie Ag Lichtstabile, brivudinhaltige pharmazeutische Formulierung zur Behandlung von Augenherpes (Herpes Ophthalmicus)
CA2651868C (en) * 2006-05-13 2014-11-25 Lg Electronics Inc. Method of performing procedures for initial network entry and handover in a broadband wireless access system
DE602007005697D1 (de) * 2006-12-05 2010-05-12 Marinomed Biotechnologie Gmbh Verwendung von carrageenan zur behandlung von rhinovirus-infektionen
CA2696009C (en) 2007-08-24 2016-08-02 Marinomed Biotechnologie Gmbh Antiviral composition comprising a sulfated polysaccharide
US9481856B2 (en) 2008-06-09 2016-11-01 Bausch & Lomb Incorporated Pharmaceutical formulations comprising stabilized polysaccharides and source of hydrogen peroxide
CN102065869B (zh) * 2008-07-01 2014-10-08 玛丽诺姆德生物技术公司 抗过敏的海洋生物聚合物
US20100086512A1 (en) 2008-10-02 2010-04-08 Rolf Schaefer Mucomimetic compositions and uses therefore
SG181421A1 (en) * 2009-12-22 2012-07-30 Marinomed Biotechnologie Gmbh Synergistic antiviral composition and use thereof
WO2012000055A1 (en) * 2010-07-02 2012-01-05 Brien Holden Vision Institute Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease
CN102988280B (zh) * 2012-10-08 2014-03-19 新乡医学院 一种加雷沙星滴眼剂

Also Published As

Publication number Publication date
WO2015110429A1 (en) 2015-07-30
HUE044329T2 (hu) 2019-10-28
EP2898888B1 (en) 2019-04-24
EP2898888B8 (en) 2019-06-12
SI2898888T1 (sl) 2019-06-28
EP3096766A1 (en) 2016-11-30
PT2898888T (pt) 2019-07-16
CA2937402A1 (en) 2015-07-30
JP2017503841A (ja) 2017-02-02
WO2015110430A1 (en) 2015-07-30
PL2898888T3 (pl) 2019-09-30
US20160331776A1 (en) 2016-11-17
ES2734269T3 (es) 2019-12-05
DK2898888T3 (da) 2019-06-03
EP2898888A1 (en) 2015-07-29
CN105939720B (zh) 2020-01-31
ES2791360T3 (es) 2020-11-04
RS58731B1 (sr) 2019-06-28
HRP20191050T1 (hr) 2019-09-06
EP3096766B1 (en) 2020-02-26
JP6635343B2 (ja) 2020-01-22
US10220055B2 (en) 2019-03-05
CA2937402C (en) 2022-07-12
CN105939720A (zh) 2016-09-14

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
MX2018000285A (es) Composicion para desobstruir la nariz congestionada que tiene actividad antiviral.
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
PH12018501001A1 (en) Therapeutic compositions for treatment of human immunodeficiency virus
MX368504B (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
PH12015502013B1 (en) Pharmaceutical composition of s-ketamine hydrochloride
PH12015501957A1 (en) Pharmaceutical composition of s-ketamine hydrochloride
MX2022009352A (es) Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c.
HRP20240166T1 (hr) Postupak liječenja prader-willijevog sindroma
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
MX2016001422A (es) Composicion farmaceutica de fingolimod.
MX2017001461A (es) Terapia de combinacion.
MX2016009475A (es) Composiciones efectivas contra la conjuntivitis viral.
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
BR112018012947A2 (pt) composições para higiene pessoal
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция
WO2016016820A3 (en) Anionically modified n-sulfonic polyallylamine derivative, pharmaceutical composition comprising the n-sulfonic polyallylamine derivative as the active substance and use of said derivate for the production of a medicine
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
MX2015012575A (es) Novedosos derivados de acrilamida como agentes contra la malaria.
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
GR1008380B (el) Φαρμακευτικο σκευασμα περιεχον ενα αντιικο παραγοντα και μεθοδος για την παρασκευη αυτου
IN2014MU01179A (es)
TH168085B (th) ยาเตรียมของการรวมกันทางเภสัชกรรมที่ประกอบด้วยตัวยับยั้งเอนไซม์เอชเอ็มจี-โคเอ รีดัคเตส และ ตัวยับยั้งการดูดซึมคลอเลสเตอรอล
WO2014109725A3 (en) Use of glycyl glutamine against depression

Legal Events

Date Code Title Description
FG Grant or registration